Navigation Links
Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
Date:3/17/2009

ROCKVILLE, Md., March 17 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will report its 2008 fourth quarter financial results in a press release to be issued after 8:00 a.m. Eastern Time on March 30, 2009. The Company will hold an investor conference call to discuss its financial results at 10:00 a.m. Eastern Time on March 30, 2009. The call will be hosted by Novavax President and Chief Executive Officer Dr. Rahul Singhvi and other members of senior management. A question and answer session will follow the financial results overview. The dial-in number for the conference call is USA and Canada (866) 206-6509 International: (703) 639-1108.

A live audio webcast of the conference call will be available at www.novavax.com. Please connect to this website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. A replay of the webcast will be available for 90 days after the webcast and a replay of the conference call will also be available by telephone beginning 1pm EDT. March 30, 2009 through midnight April 1, 2009. To access the replay, dial (888) 266-2081 and enter pass code 1334845.

About Novavax, Inc.

Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.

Forward Looking Statements

Statements herein relating to future development results and performance, conditions or strategies and other matters, including expectations regarding product and clinical developments, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of Novavax's product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before regulatory approval can be applied for and the FDA may not approve a vaccine even if further trial results are similar to those disclosed previously by the company; uncertainties relating to clinical trials, including possible delays in initiating or completing the trials and safety and efficacy results; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
2. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
3. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
4. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
5. Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009
6. NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate
7. Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008
8. Novavax CEO to Present at Piper Jaffray 20th Annual Healthcare Conference
9. Novavax CEO to Present at Lazard Capital Markets 5th Annual Healthcare Conference
10. Novavax Announces Release Date of 2008 Third Quarter Financial Results and Investor Conference Call
11. Novavax CEO to Present at Oppenheimer 19th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results ... --> --> For the fourth quarter ... or $0.34 loss per share, compared to a net loss of ... in 2014. For the year ended December 31, 2015, the Company ... share, as compared to a net loss of $60.5 million, or ...
(Date:2/11/2016)... and GERMANTOWN, Maryland , ... Frankfurt Prime Standard: QIA) today announced the introduction of ... gene expression profiling, expanding QIAGEN,s portfolio of Sample to ... researchers to select from over 20,000 human genes and ... between genes, cellular phenotypes and disease processes. --> ...
(Date:2/11/2016)... Feb. 11, 2016  Spectra BioPharma Selling Solutions (Spectra) ... provides biopharma companies the experience, expertise, operational delivery ... outsourced sales teams. Created in concert with industry ... the strategic and tactical needs of its clients ... through both personal and non-personal promotion. ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... to delivering cutting-edge information focused on the development and manufacture of biopharmaceuticals ... a premier sponsor of the 2016 BioProcess International Awards – Recognizing Excellence ...
Breaking Biology Technology:
(Date:1/20/2016)... LONDON , Jan. 20, 2016 A ... positioned to directly benefit from the explosion in genomics ... from Howe Sound Research. A range of dynamic trends ... ...... - personalized medicine - pharmacogenomics - pathogen ... economies with large markets - greater understanding of the ...
(Date:1/15/2016)... Jan. 15, 2016 Recent publicized breaches in ... find new ways to ensure data security and user ... and Android that ties a user,s ... it into a hardware authorization token. Customer service agents ... fingerprint on their KodeKey enabled device to verify their ...
(Date:1/11/2016)... Jan. 11, 2016  higi, the leading retail ... retail locations, web and mobile, today announced it ... from existing investors. --> ... to further innovate higi,s health platform – its ... portal – including expanding services and programs to ...
Breaking Biology News(10 mins):